A pivotal wet AMD win revives a program Kodiak had largely written off, sending shares up as much as 166% on a readout the company says supports regulatory fili

The investment deepens AstraZeneca's ties to Summit, whose lead asset is a PD-1/VEGF bispecific being tested against Keytruda-era standards in lung cancer.

The deal adds an implantable depot delivery platform to Novo's obesity portfolio as analysts debate whether the company is hedging across multiple technologies.

An FDA advisory panel endorsement would mark a major regulatory step for multi-cancer early detection, with Samsung moving in parallel on Korean distribution an

Extending the policy to Medicaid broadens a pricing regime that drugmakers have warned could curb US launches and global reference pricing.

The nod adds an oral option to AbbVie's Parkinson's franchise, which is facing eventual erosion of Duodopa and other older products.

Rising deal flow for Chinese assets reflects both the volume of early-stage candidates there and pressure on Western pharma to refill pipelines cheaply.

The termination trims Roche's obesity pipeline and returns emugrobart to Chugai, which says it will refocus on SMA and other programs.

The label expansion makes Olumiant the first JAK inhibitor cleared for autoimmune hair loss in adolescents, widening a market Lilly already serves in adults.

Mirum is positioning its hepatitis D candidate against Gilead and Vir, where the company says 56% of treated patients met virus and liver targets versus none in

The supplemental filing would extend elinzanetant beyond menopause-related vasomotor symptoms into a breast cancer treatment population.

The shift in framing matters for payer coverage decisions and for telehealth players expanding beyond weight loss into testosterone and other categories.

The listing tests investor appetite for RNA-editing and silencing platforms after a strong run in biotech equities.

Domestic players including Chong Kun Dang affiliates and Onconic are adding obesity candidates as global GLP-1 demand reshapes the metabolic pipeline.

The 40-patient study found higher good cholesterol but no significant liver-fat difference, undercutting the NASH/MASH thesis.

The program is aimed at widening obesity and diabetes access beyond high-income markets, where Lilly faces pricing scrutiny.

The tie-up pairs an AI-discovered oral incretin with 3SBio's commercial reach in a crowded Chinese obesity market.

The package would reshape EU incentives, regulatory data protection, and market access rules that drugmakers have lobbied over for years.